Arvinder Cheema, Sajjad Ali* and Pranatharthi Chandrasekar
Invasive Aspergillosis (IA) is a severe opportunistic infection that typically affects immunocompromised patients. Ruxolitinib is a selective Janus kinase inhibitor which is used for steroid-refractory acute Graft-vs.-Host Disease (GVHD). Several case reports have described serious opportunistic infections in Ruxolitinib-treated Primary Myelofibrosis (PMF) patients but no routine antifungal prophylaxis is recommended in these patients. We present an interesting case of 77-year-old man with previous history of treated MDS several years ago currently on Ruxolitinib for GVHD who was found to have new cavitary lung lesion on routine imaging.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 